Oncocyte is now iMDx! Click here to learn more.

Publications

Which medical specialty are you interested in?

CLICK OR SCROLL DOWN FOR AN OVERVIEW OF EACH

Transplant Publications

BY

Transplant Publications

Akifova A, Budde K, Choi M, et al. (2025). Association of Blood Donor-derived Cellfree DNA Levels With Banff Scores. Transplant Direct 11: e1794; doi: 10.1097/TXD.0000000000001794

Akifova A, Budde K, Oellerich M, et al. (2024). Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications. Transplant International doi:10.3389/ti.2024.13239

Mayer KA, Schrezenmeier E , Diebold M, et al. (2024). A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. NEJM doi:10.1056/NEJMoa2400763

Osmanodja B, Akifova A, Budde K, et al. (2024). Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. Transplant International doi:10.3389/ti.2024.13213

Akifova A, Budde K, Choi M, et al. (2023). Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation. Kidney International Reports doi:10.1016/j.ekir.2023.07.011

Baumann AK, Beck J, Kirchner T, et al. (2022). Elevated Fractional Donor-Derived Cell-Free DNA During Subclinical Graft Injury After Liver Transplantation. Liver Transpl 28(12):1911-1919

Knüttgen F, Beck J, Dittrich M, et al. (2022). Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors. Transplantation 106(3):615-622

Oellerich M, Sherwood K, Keown P, et al. (2021). Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol 17(9):591-603

Osmanodja B, Akifova A, Budde K, et al. (2021). Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. Transplant Direct 7(11):e778

Schütz E, Asendorf T, Beck J, et al. (2020) Time-dependent apparent increase in dd-cfDNA percentage in clinically stable patients between one and five years following kidney transplantation. Clin Chem 66(10):1290-99

Oellerich M, Shipkova M, Asendorf T, et al. (2019) Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 19(11):3087-99

Beck J, Oellerich M, Schütz E. (2018). A Universal Droplet Digital PCR Approach for Monitoring of Graft Health After Transplantation Using a Preselected SNP Set. Methods Mol Biol 1768:335-48

Schütz E, Fischer A, Beck J, et al. (2017). Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med 14(4):e1002286

Oellerich M, Beck J, Kanzaw P, et al. (2016). Graft-derived cell-free DNA as a marker of graft integrity after transplantation. Ther Drug Monit 38:153-76

Beck J, Oellerich M, Schulz U, et al. (2015). Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. Transplant Proc 47(8):2400-3

Kanzaw P, Kollmar O, Schütz E, et al. (2014). Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation 98(5):e43-5

Oellerich M, Schütz E, Kanzow P, et al. (2014). Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 36(2):136-40

Beck J, Bierau S, Balzer S, et al. (2013). Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 59(12):1732-41

Oncology Publications

BY

Oncology Publications

Dugo M, Huang C, Egle D, et al. (2024). The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 30 (21): 4900–4909

Klinsing S, Beck J, Weber K, et al. (2024). Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients. Acta Neuorpathologica Communications. 12:177

Antoniotti C, Boccaccino A, Seitz R, et al. (2023). An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clin Cancer Res CCR-22-3878

Nielsen T, Varga M, Cronister C, et al. (2023). The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer immunology, immunotherapy: CII, 10.1007/s00262-023-03401-x

Page D, Pucilowska J, Chun B, et al. (2023). A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer 9(1):53

Saltman D, Varga M, Nielsen T, et al. (2023). 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clin Lung Cancer 24(2):137-144

Ranganath H, Jain A, Smith J, et al. (2022). Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC cancer 22:407

Seitz R, Hurwitz M, Nielson T, et al. (2022). Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients. J Transl Med 20:370

Spring L, Bar Y, Isakoff S. (2022). The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. J Natl Compr Canc Netw 20(6):723-734

Iwase T, Blenman K, Li X, et al. (2021). A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 13(19):4839

Nielsen T, Ring B, Seitz R, et al. (2021). A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 7(3):e06438

Saltman D, Nielsen T, Salina D, et al. (2021). Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab. Ther Adv Med Oncol 13:17588359211010156

Schirmer M, Beck J, Leu M, et al. (2018). Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. Clin Chem 64(6):959-970

Weiss G, Blaydorn L, Beck J, et al. (2018). Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs 36(1):96-102

Weiss G, Beck J, Braun D, et al. (2017). Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clin Cancer Res 23(17):5074-5081

Schütz E, Akbari MR, Beck J, et al. (2015). Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 61(1):239-248

Connect With Our Experts

Take the first step toward specialized, compassionate care in transplant and oncology. Whether you’re seeking information, looking to schedule a consultation.

Follow Us

Company

Transplant

GraftAssureCore^TM

GraftAssureDx^TM

GraftAssureIQ^TM

Legal

Website Terms of Use

Terms and Conditions of Sale

HIPAA Notice of Privacy Practices

©2025 Insight Molecular Diagnostics Inc. All rights reserved. iMDx, GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO, DetermaCNI, and OncoTIME are trademarks of Insight Molecular Diagnostics Inc. All other trademarks are the property of their respective owners. For the intended uses of all products, please refer to www.imdxinc.com.

WEBSITE BY: LEFT HAND DESIGN